Latest News Ocutrx Receives Fifth Patent for In-home Visual Field Test Monitoring and Alerting By Staff Thursday, May 6, 2021 12:21 AM IRVINE, Calif.—Ocutrx Technologies, an augmented/extended reality and surgical device maker, announced the issuance of its fifth patent by the U.S. Patent & Trademark Office. The fifth patent covers a Macular Visual Field (MVF) test administered while the user is wearing the OcuLenz AMD AR/XR headset. The patented technology is primarily associated with the at-home monitoring of individuals with Age-Related Macular Degeneration (AMD). This new patent encompasses taking a visual field test while wearing Ocutrx’s low-vision AR headset, the Oculenz AMD. The MVF test provides the OcuLenz AMD headset with information for pixel-shifting for vision correction providing AMD sufferers a better ability to read, recognize faces, and accomplish everyday tasks. Ocutrx’s initial clinical trials showed a mean improvement from vision worse than 20/200 up to 20/65. The clinical trial validated the visual field test process which permitted patients who had not been able to read prior to the trial to be able to read in just one session while wearing the Oculenz AMD headset, Ocutrx said. “This technology is revolutionary for the low-vision industry because it allows the patient to set the headset to a ‘self-diagnostic’ mode which self-refines and adjusts the pixel manipulation to match any changes or advancing of their eye disease,” said Dr. Thomas Finley, chairman of Ocutrx Technologies international advisory board, and co-founder and president of Tulsa Retina Consultants, the largest retina practice serving northeast Oklahoma.Ocutrx currently has 114 pending patents in multiple countries.